» Articles » PMID: 19181844

Cytokine-induced Memory-like Natural Killer Cells

Overview
Specialty Science
Date 2009 Feb 3
PMID 19181844
Citations 443
Authors
Affiliations
Soon will be listed here.
Abstract

The mammalian immune response to infection is mediated by 2 broad arms, the innate and adaptive immune systems. Innate immune cells are a first-line defense against pathogens and are thought to respond consistently to infection, regardless of previous exposure, i.e., they do not exhibit memory of prior activation. By contrast, adaptive immune cells display immunologic memory that has 2 basic characteristics, antigen specificity and an amplified response upon subsequent exposure. Whereas adaptive immune cells have rearranged receptor genes to recognize the universe of antigens, natural killer (NK) cells are innate immune lymphocytes with a limited repertoire of germ-line encoded receptors for target recognition. NK cells also produce cytokines such as IFN-gamma (IFN-gamma) to protect the host during the innate response to infection. Herein, we show that cytokine-activated NK cells transferred into naïve hosts can be specifically detected 7-22 days later when they are phenotypically similar to naïve cells and are not constitutively producing IFN-gamma. However, they produce significantly more IFN-gamma when restimulated. This memory-like property is intrinsic to the NK cell. By contrast, memory-like NK cells do not express granzyme B protein and kill targets similarly to naïve NK cells. Thus, these experiments identify an ability of innate immune cells to retain an intrinsic memory of prior activation, a function until now attributed only to antigen-specific adaptive immune cells.

Citing Articles

CD56 cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells.

Guevara Lopez M, Gebo A, Parodi M, Persano S, Maus-Conn J, Mingari M J Immunother Cancer. 2025; 13(2).

PMID: 39939140 PMC: 11822435. DOI: 10.1136/jitc-2024-010205.


From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.

Laeremans T, Janssens A, Aerts J Immunotherapy. 2025; 17(2):133-145.

PMID: 39905963 PMC: 11901454. DOI: 10.1080/1750743X.2025.2460965.


What's in a name? Memory NK cells for cancer immunotherapy.

Judge S, Purl M, Murphy W, Canter R J Immunother Cancer. 2025; 13(1).

PMID: 39890423 PMC: 11792271. DOI: 10.1136/jitc-2024-010850.


Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.

Nayak I, Biondo R, Stewart W, Fulton R, Moker N, Zhang C Immunol Cell Biol. 2025; 103(2):192-212.

PMID: 39865344 PMC: 11792776. DOI: 10.1111/imcb.12848.


Engineered Cellular Therapies for the Treatment of Thoracic Cancers.

Erickson S, Manning B, Kumar A, Patel M Cancers (Basel). 2025; 17(1.

PMID: 39796666 PMC: 11718842. DOI: 10.3390/cancers17010035.


References
1.
Young H, Bream J . IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol. 2007; 316:97-117. DOI: 10.1007/978-3-540-71329-6_6. View

2.
Smith H, Chuang H, Wang L, Salcedo M, Heusel J, Yokoyama W . Nonstochastic coexpression of activation receptors on murine natural killer cells. J Exp Med. 2000; 191(8):1341-54. PMC: 2193132. DOI: 10.1084/jem.191.8.1341. View

3.
French A, Yokoyama W . Natural killer cells and viral infections. Curr Opin Immunol. 2002; 15(1):45-51. DOI: 10.1016/s095279150200002x. View

4.
Andrews D, Scalzo A, Yokoyama W, Smyth M, Degli-Esposti M . Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol. 2002; 4(2):175-81. DOI: 10.1038/ni880. View

5.
Bustamante J, Boisson-Dupuis S, Jouanguy E, Picard C, Puel A, Abel L . Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol. 2007; 20(1):39-48. DOI: 10.1016/j.coi.2007.10.005. View